Christus Stehlin Foundation for Cancer Research

This is a phase I and pharmacology study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients with Solid Tumors or Lymphoma.
OBJECTIVES
Primary:
To describe the dose limiting toxicities and adverse event profile of Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day.
To determine Phase II recommended dose of Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day.
Secondary:
To perform a pharmacokinetic study of orally administered CZ48 in the plasma.
To assess responses by RECIST criteria.
To follow patients for survival.